Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA for patients with cancer
BEIJING, SHANGHAI and BOSTON, March 22, 2023. Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck& Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio ' s CD73 monoclonal antibody... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J.--(BUSINESS WIRE) March 16, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe-002 is evaluating... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 17, 2023 Category: Pharmaceuticals Source Type: clinical trials
Greenphire Expands Agreement with Merck to Help Reduce Financial and Travel Barriers for Clinical Trial Participants Worldwide
KING OF PRUSSIA, Pa., March 13, 2023 . Greenphire, the global leader in financial lifecycle management for clinical trials, today announced an expansion of its agreement with Merck, known as MSD outside the United States and Canada. This expanded... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck ’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
RAHWAY, N.J.--(BUSINESS WIRE) March 6, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck’s novel investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 6, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck ’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
RAHWAY, N.J.--(BUSINESS WIRE) March 6, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2b clinical trial evaluating MK-0616, an investigational, once-daily oral proprotein... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 6, 2023 Category: Pharmaceuticals Source Type: clinical trials
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With Keytruda (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection
CAMBRIDGE, M.A., and RAHWAY, N.J., Feb. 22, 2023– Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
Condition: Acute Malaria Interventions: Drug: M5717 330 mg; Drug: M5717 500 mg; Drug: M5717 660 mg; Drug: Pyronaridine 360 mg; Drug: Pyronaridine 540 mg; Drug: Pyronaridine 720 mg; Drug: Pyronaridine-artesunate (Pyramax) 360 mg/120 mg; Drug: Pyronaridine- artesunate (Pyramax) 540 mg/180 mg; Dr ug: Pyronaridine-artesunate (Pyramax) 720 mg/240 mg Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2023 Category: Research Source Type: clinical trials
